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Inflammation has emerged as a key component 
of the metabolic syndrome. The canonical 
NF-B pathway is a well-studied regulator of 
inflammatory processes and is heavily implicated 
in insulin resistance and  cell dysfunction in 
diabetes. Inhibition of NF-B improved glucose 
tolerance in human and animal studies (Yuan et al., 
2001; Hundal et al., 2002; Goldfine et al., 2013). 
The IB-like kinases IKK- and TANK-binding 
kinase (TBK1) are downstream NF-B targets 
involved in driving insulin resistance (Chiang 
et al., 2009) and blockade of IKK- and TBK1 
improves metabolic function in obesity (Reilly 
et al., 2013). Thus, canonical NF-B is a central 
molecular pathway in obesity-dependent changes 
in the metabolic syndrome.
A divergent arm of NF-B signaling is the 
noncanonical NF-B pathway mediated by NF-
B–inducing kinase (NIK), which is activated 
downstream of TNF receptor (TNFR) family 
members including TNFR2, receptor activator 
of NF-B (RANK), lymphotoxin  receptor 
(LTR), or CD40 upon ligand binding (Sun, 
2011). NIK levels and hence its activation are 
controlled by an E3 ligase complex; TNFR- 
associated factor 2 (TRAF2) recruits the E3 
ligases baculoviral IAP repeat-containing proteins 
2 and 3 (BIRC2/3), whereas interactions with 
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The nuclear factor B (NF-B) pathway is a master regulator of inflammatory processes 
and is implicated in insulin resistance and pancreatic  cell dysfunction in the metabolic 
syndrome. Whereas canonical NF-B signaling is well studied, there is little information on 
the divergent noncanonical NF-B pathway in the context of pancreatic islet dysfunction. 
Here, we demonstrate that pharmacological activation of the noncanonical NF-B–inducing 
kinase (NIK) disrupts glucose homeostasis in zebrafish in vivo. We identify NIK as a critical 
negative regulator of  cell function, as pharmacological NIK activation results in impaired 
glucose-stimulated insulin secretion in mouse and human islets. NIK levels are elevated in 
pancreatic islets isolated from diet-induced obese (DIO) mice, which exhibit increased pro-
cessing of noncanonical NF-B components p100 to p52, and accumulation of RelB. TNF 
and receptor activator of NF-B ligand (RANKL), two ligands associated with diabetes, induce 
NIK in islets. Mice with constitutive  cell–intrinsic NIK activation present impaired insulin 
secretion with DIO. NIK activation triggers the noncanonical NF-B transcriptional network 
to induce genes identified in human type 2 diabetes genome-wide association studies linked 
to  cell failure. These studies reveal that NIK contributes a central mechanism for  cell 
failure in diet-induced obesity.
© 2015 Malle et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http://www.rupress.org/terms). After six months it is available 
under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 
Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Figure 1. MV1 disrupts glucose homeostasis in zebrafish and impairs  cell function in human and mouse islets. (A) Protein levels of NIK and 
p100 to p52 processing in the MDA-MB-231/Luc breast cancer cell line treated with increasing concentrations of MV1 were assessed by immunoblotting. 
A representative of four independent experiments is shown. Histogram data depicts cumulative densitometry relative to -actin of the four independent 
experiments. (B) Glucose levels in zebrafish larvae injected with DMSO or MV1 were assessed. The data are mean and SEM derived from seven control and five 
MV1-treated groups, with four larvae per group, in a representative of two independent experiments. **, P < 0.01. (C) Protein levels of p100 to p52 processing 
in DMSO and MV1-treated C57BL/6 mouse islets from one islet isolate were assessed by immunoblotting. A representative of three independent experi-
ments is shown. Histogram data depicts cumulative densitometry relative to -actin of the three independent experiments. (D) In vitro GSIS in 2 and  
20 mM d-glucose and in KCl conditions of DMSO control and MV1-treated primary mouse islets was measured. Data are mean and SEM derived from  
six independent islet isolates for each group, and are representative of two independent experiments. **, P < 0.01. (E–G) Blood glucose and AUC were 
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regulating NIK impairs  cell insulin secretory capacity in a 
diet-induced obesity model in mice. Here, for the first time, 
we demonstrate a novel function for NIK and subsequent 
noncanonical NF-B activation as a negative regulator of pan-
creatic  cell function, impairing insulin secretion in diet- 
induced obesity. NIK activation in the metabolic syndrome 
is a feature of pancreatic  cells but also insulin-dependent 
peripheral tissues, thereby providing a tissue-spanning mech-
anism to link inflammation with multiple tissue failure in dia-
betes pathogenesis.
RESULTS
Systemic monovalent 1 (MV1) administration  
impairs glucose homeostasis in zebrafish in vivo
Aberrant BIRC function has been associated with many human 
cancers (Fulda and Vucic, 2012), leading to the development of 
a group of peptide-derived drugs called second mitochondria-
derived activator of caspase (SMAC) mimetics, which induce 
the degradation of BIRC2 and BIRC3, thereby interfering 
with their ability to inhibit apoptosis (Varfolomeev et al., 2007). 
Concomitantly, degradation of BIRC2 and BIRC3 elicits NIK 
accumulation, which leads to proteasome-dependent processing 
of p100 into p52 and hence activates the noncanonical NF-B 
pathway (Varfolomeev et al., 2007).
To test whether systemic elevation of NIK mediated by 
the SMAC mimetic MV1 would alter glucose homeostasis 
in vivo, we used a zebrafish model. The main organs required 
for metabolic control, such as the pancreas, islet, and insulin-
sensitive tissue (muscle, liver) are conserved in zebrafish, ren-
dering it an excellent model to study glucose homeostasis 
(Hesselson et al., 2009; Jurczyk et al., 2011; Seth et al., 2013). 
First, we showed that synthesized MV1 could induce NIK 
accumulation and processing of p100 into p52 in MDA-MB-
231/Luc breast cancer cells, indicating activation of nonca-
nonical NF-B signaling (Fig. 1 A), as described previously 
(Varfolomeev et al., 2007). We next injected MV1 into zebra-
fish larvae at 6 d postfertilization (dpf) and examined glucose 
levels after 6 h. WT larvae treated with MV1 exhibited in-
creased glucose levels compared with vehicle (DMSO) controls 
(Fig. 1 B). This indicates that MV1-induced NIK activation 
disrupts glucose homeostasis in vivo in WT zebrafish.
MV1 administration activates NIK in mouse and human 
islets and impairs glucose-stimulated insulin secretion
To elucidate whether the defect in glucose homeostasis re-
lates to MV1-induced, NIK-mediated  cell dysfunction, we 
TRAF3 allows delivery of NIK to the complex (Vallabhapurapu 
et al., 2008; Zarnegar et al., 2008). In the absence of a ligand, 
NIK is ubiquitinated by this complex and targeted for pro-
teasome-dependent degradation, thereby silencing the nonca-
nonical NF-B pathway (Vallabhapurapu et al., 2008; Zarnegar 
et al., 2008). The noncanonical NF-B dimer regulates gene 
expression through binding to general, as well as specific, non-
canonical B target sites (Bonizzi et al., 2004); however, its 
targets and the phenotypic consequence of its activation 
are incompletely known. Studies show that noncanonical 
NF-B pathway activation mediated through loss of TRAF2 
or TRAF3 promotes expansion of B cells (Gardam et al., 2008), 
and leads to a shift in the proportions of specific T cell sub-
populations (Xie et al., 2011). Recently, activation of the non-
canonical NF-B pathway has been linked to the metabolic 
syndrome (Choudhary et al., 2011; Sheng et al., 2012; Kiechl 
et al., 2013). For example, NIK levels are high in muscle biop-
sies of obese patients, but decline after gastric bypass surgery, 
weight loss, and a decrease in insulin resistance (Choudhary 
et al., 2011).
Emerging evidence emphasizes a crucial role for pancreatic 
 cell dysfunction in type 2 diabetes (T2D). Genome-wide 
association studies (GWAS) have identified a large number of 
loci associated with  cell function and survival (Florez, 2008; 
Guan et al., 2008; Taneera et al., 2012). Further, hyperglyce-
mia (Donath et al., 1999), circulating inflammatory factors 
(Spranger et al., 2003), or amyloid production in the islet 
(Verchere et al., 1996) are deleterious for islets and contribute 
to T2D pathogenesis. This is indicated by diminished  cell 
mass (Butler et al., 2003), but also by reduced  cell secretory 
function in T2D patients (Ferrannini and Mari, 2014). Thus, 
 cell dysfunction in diabetes pathogenesis is now being 
acknowledged as a critical and major contributor in diabetes 
pathogenesis. However, the mechanisms for loss of  cell func-
tion and mass are incompletely known. Therefore, it is essential 
to elucidate factors that contribute to both insulin resistance 
in peripheral tissue and  cell failure.
Core components of the noncanonical NF-B pathway 
have been identified in pancreatic islets (Ortis et al., 2010); 
however, the functional consequence of NIK and subsequent 
noncanonical NF-B activation in  cells is completely un-
known. We demonstrate here that pharmacologically induced 
NIK disrupts glucose homeostasis in vivo in a zebrafish model 
and impairs glucose-stimulated insulin secretion in mouse and 
human islets. Additionally, a high-fat diet triggers  cell–intrinsic 
NIK activation and disruption of the E3 ligase control circuit 
determined in DMSO control and MV1-treated mouse islet C57BL/6 transplant recipients after i.p. injection of d-glucose at (E) POD 3 (AUC, **, P < 0.01; 
control, n = 9; MV1, n = 8), (F) POD 7 (*, P < 0.05; control, n = 12; MV1, n = 13), and (G) POD 11 (n.s.; control, n = 10; MV1, n = 10). Data are representa-
tive of three independent mouse cohorts tested. (H) H&E staining and insulin immunostaining of DMSO control and MV1-treated mouse islet grafts are 
shown. Graft  cell area was determined for three DMSO and three MV1-treated islet grafts by quantification of insulin-positive area in continuous serial 
graft sections. A representative image for each condition is shown. Boxed insets represent magnified area. Differences in graft area are not significant.  
*, P > 0.05. Bar, 100 µm. (I) In vitro GSIS in 2.8 and 25 mM d-glucose conditions of DMSO control and MV1-treated primary human islets was measured. 
Data are mean and SEM derived from quintuplets for DMSO and MV1-treated islets and are representative of three independent human islet isolates.  
*, P < 0.05. All data are represented as mean ± SEM; p-values were determined using Student’s t test.
 
D
ow
nloaded from
 https://rupress.org/jem
/article-pdf/212/8/1239/607802/jem
_20150218.pdf by U
niversity O
f D
undee Library & Learning C
entre user on 20 February 2020
1242 NIK links inflammation to  cell dysfunction | Malle et al.
Figure 2.  Pancreatic islets in a DIO model exhibit NIK hyperactivation and display a net  cell secretory defect. (A) Blood glucose and AUC 
were determined in 12 chow (dotted line) and 15 DIO (solid line) fed C57BL/6 WT mice (16 wk old) after i.p. injection of d-glucose. Data are representative 
of three independent mouse cohorts tested. ****, P < 0.0001. (B) Insulin levels and AUC (10 min after injection) were determined for 5 chow (dotted line) 
and 15 DIO (solid line) fed C57BL/6 WT mice (16 wk old) after i.v. injection of d-glucose. Data are representative of three independent mouse cohorts 
tested. *, P < 0.05. (C) Total  cell area was determined for 5 chow- and 5 HFD-fed WT mice by quantification of insulin-positive area in serial graft sec-
tions as a percentage of total pancreatic exocrine area (*, P < 0.05). (D) Data are mean and SEM showing percentage of net insulin secretion normalized 
to mean  cell area determined for mice in C. (left) Net fasted insulin levels; (right) net secretion (AUC) for 10 min after d-glucose injection. *, P < 0.05; 
****, P < 0.0001. (E) Protein levels of NIK, IKK/ phosphorylation, IB, p100 to p52 processing, and RelB in one islet isolate from a chow-fed and a DIO 
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and increased phosphorylation of the NIK downstream target 
IB kinase  (IKK). Activated phospho-IKK phosphory-
lates NF-B p100, leading to its proteasome-dependent cleav-
age releasing active p52. Islets from DIO mice exhibited a 
higher processing rate of NF-B p100 to p52 and increased 
levels of the p52 binding partner RelB, compared with islets 
from chow-fed controls. As the antibody for Phospho-IKK 
not only identifies phospho-IKK but also phospho-IKK, 
we probed for IKK downstream target IB, which is the 
canonical NF-B inhibitor; IB levels were normal, indi-
cating absence of canonical NF-B activation in DIO islets.
TNF and RANKL trigger NIK activation in primary islets
Both TNF and receptor activator of NF-B ligand (RANKL) 
activate the noncanonical NF-B pathway in various cell types, 
including immune cells (Rauert et al., 2010) and osteoclasts 
(Novack et al., 2003), and high circulating serum levels of 
TNF and RANKL are associated with diabetes (Hotamisligil 
et al., 1995; Kiechl et al., 2013). The effect of TNF and RANKL 
on noncanonical NF-B signaling in islets is unknown. TNF 
induced p100 to p52 processing and RelB accumulation in 
primary mouse islets, indicating NIK activation (Fig. 2 F). 
TNF also induced canonical NF-B activation as shown by 
degradation of its inhibitor IB. RANKL induced p100 to 
52 processing and RelB accumulation in primary islets, indi-
cating NIK activation, but did not activate canonical NF-B 
signaling (Fig. 2 G). Therefore, both TNF and RANKL acti-
vate NIK signaling in primary mouse islets. Additionally, is-
lets isolated from HFD-fed mice show cell-intrinsic activation 
of NIK and activation of the noncanonical NF-B pathway 
with reduced insulin secretion.
Cell-intrinsic NIK activation negatively regulates  cell 
function in a model of diet-induced obesity
The aforementioned data present a causal link between  cell 
dysfunction and NIK activation in DIO. To test this concept 
further, we used a genetic approach whereby  cells would 
express high levels of active NIK in a cell-intrinsic manner. 
NIK levels, and hence its activation, are controlled by an E3 
ligase complex; TRAF2 recruits the E3 ligases BIRC2/3 while 
interactions with TRAF3 allow delivery of NIK to the com-
plex (Vallabhapurapu et al., 2008; Zarnegar et al., 2008). In 
absence of a ligand, NIK is ubiquitinated by this complex and 
targeted for proteasome-dependent degradation thereby silenc-
ing the noncanonical NF-B pathway (Vallabhapurapu et al., 
2008; Zarnegar et al., 2008). Deletion of any one component, 
i.e., TRAF2, TRAF3, or the BIRC proteins, results in cell-
intrinsic hyperactivation of noncanonical NF-B pathway at 
a physiological level (Gardam et al., 2008; Zarnegar et al., 2008).
examined the effect of MV1 on insulin secretion of primary 
C57BL/6 WT islets. Addition of MV1 to WT islets triggered 
p100 to p52 processing, indicating NIK activation (Fig. 1 C). 
MV1 had no effect on islet survival in 24-h in vitro cultures 
as assessed by calcein-AM uptake and ethidium homodimer 
DNA intercalation (unpublished data). In a glucose-stimulated 
insulin secretion (GSIS) assay, MV1-treated islets exhibited 
normal basal insulin output, but insulin secretion was reduced 
by 50% compared with controls when challenged with 
20 mM glucose. Potassium chloride (KCl)–stimulated secre-
tion was normal, indicating normal insulin content (Fig. 1 D). 
To assess the effect of MV1-treatment in vivo, we transplanted 
either MV1- or vehicle-treated islets into diabetic syngeneic 
recipients. A glucose tolerance test (GTT) at post-operative 
day (POD) 3 revealed that, compared with controls, MV1-
treated grafts exhibited impaired glucose tolerance (Fig. 1 E). 
Glucose tolerance was still slightly impaired at POD 7, but 
had completely resolved by POD 11 such that MV1-treated 
islets provided equivalent metabolic control to vehicle treated 
islets (Fig. 1, F and G). Further, MV1-treated grafts exhib-
ited normal morphology and insulin staining, as well as equiv-
alent graft area determined by morphometry (Fig. 1 H). This 
indicates that acute activation of NIK results in a temporary 
 cell defect that is reversed upon drug-clearance and sup-
pression of NIK.
NIK activation impairs glucose-stimulated insulin secretion 
in human islets
We next assessed whether  cell–intrinsic activation of NIK 
would impair the function of human islets. Human islets treated 
with MV1 showed normal basal (2.8 mM) but defective 
glucose-stimulated (25 mM) insulin secretion (Fig. 1 I). Thus, 
activation of NIK in human islets resulted in impaired  cell 
function. These data highlight the importance of the NIK 
pathway and its contribution to  cell dysfunction in human 
islet physiology.
NIK is activated in islets in diet-induced obesity
To elucidate whether NIK plays a role in islets in a model 
of glucose intolerance, a diet-induced obesity (DIO) model, 
C57BL/6 mice were placed on a 45% kcal high-fat diet (HFD). 
After 8 wk of HFD, these mice showed impaired glucose 
tolerance and insulin secretion (Fig. 2, A and B), increased 
 cell mass (Fig. 2 C), and reduced insulin output capacity in 
fasted conditions and in response to an in vivo glucose chal-
lenge (Fig. 2 D). These results are supported by previous stud-
ies (Winzell and Ahrén, 2004; Peyot et al., 2010). Islets from 
DIO mice exhibited activation of the noncanonical NF-B 
pathway (Fig. 2 E), as indicated by the accumulation of NIK 
C57BL/6 WT mouse were assessed by immunoblotting. A representative of four independent experiments is shown. Histogram data depict cumulative 
densitometry relative to -actin of the four independent experiments. (F and G) Protein levels of p100 to p52 processing and RelB in one (F) TNF- and  
(G) RANKL-stimulated mouse islet isolate at 0, 1, and 4 h after stimulation. IB levels at 0, 15, 30, 60, and 240 min after stimulation were assessed by 
immunoblotting. A representative of four independent experiments is shown. Histogram data shows cumulative densitometry relative to -actin of the 
four independent experiments. All data are represented as mean ± SEM; p-values were determined using Student’s t test.
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Figure 3. Constitutive NIK activation elicits a defect in insulin secretion. (A) TRAF2 protein levels in WT and TRAF2 islets isolated from one WT 
and one TRAF2 mouse assessed by immunoblotting. A representative of three independent islet isolates tested per genotype is shown. Histogram data 
depicts mean and SEM cumulative densitometry data relative to -actin of the three independent experiments. (B) Relative expression of islet TRAF2 
mRNA from six WT and nine TRAF2 islet isolates was determined by RT-PCR. Data are representative of two independent experiments. ***, P < 0.001.  
(C) Protein levels of NIK, IKK/ phosphorylation, IB, p100 to p52 processing, and RelB in one nonstimulated WT and one TRAF2 islet isolate were 
assessed by immunoblotting. A representative of three independent experiments is shown. Histogram data depicts cumulative densitometry relative to  
-actin of the three independent experiments. (D) Non-fasted blood glucose levels were determined in 30 TRAF2loxP/loxP (WT), 10 RI Cre (WT), and 24 TRAF2 
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I and J). However, in the DIO model, TRAF2 mice ex-
hibited increased pancreatic insulin content compared with 
WT mice (Fig. 3 I). This is accompanied by an increase in 
 cell area in DIO TRAF2 mice (Fig. 3 J). Also,  cells in 
TRAF2 islets exhibited robust insulin expression as deter-
mined by insulin immunostaining (Fig. 3 K) and normal 
levels of Insulin-1 and Insulin-2 determined by RT-PCR 
(Fig. 3 L). Thus, we can conclude that  cell–intrinsic NIK 
activation results in a loss of insulin secretory capacity rather 
than a defect in insulin production. Additionally, we hy-
pothesize that the increased  cell mass in DIO TRAF2 
mice most likely represents a physiological compensatory 
response to the reduced insulin secretory capacity of the 
TRAF2 islet.
The function of TRAF2 islets is impaired  
after transplantation
In the DIO model, TRAF2 mice presented a blunted first-
phase insulin secretion compared with controls. A subset of 
transgenic RIP Cre mouse lines have been reported to ex-
hibit hypothalamic Cre expression (Wicksteed et al., 2010). 
To discern between hypothalamus-mediated and islet-specific 
defects, we isolated pancreatic TRAF2 and control islets, and 
transplanted 150 islet equivalents into streptozotocin-treated 
diabetic syngeneic C57BL/6 recipients. Under these conditions 
both WT and TRAF2 islet grafts restored normal metabolic 
control (Fig. 4 A). To test  cell function, we performed an 
i.p. GTT at POD 11. Compared with mice receiving WT islet 
grafts, TRAF2 graft recipients exhibited impaired glucose 
tolerance (Fig. 4 B). Next, we determined insulin secretion 
in graft recipients via an i.v. GTT at POD 21. Recipients of 
TRAF2 islet grafts exhibited a blunted first-phase insulin secre-
tion compared with mice receiving WT islet grafts (Fig. 4 C). 
Graft pathology revealed that TRAF2 grafts exhibited nor-
mal morphology and insulin staining, as well as equivalent 
graft area determined by morphometry (Fig. 4 D). Therefore, 
we conclude that loss of glucose tolerance was not due to 
 cell loss.
To examine how  cell–intrinsic NIK activation would 
affect glucose homeostasis, we generated  cell–specific TRAF2 
knockout (TRAF2) mice. TRAF2loxP/loxP were crossed with 
mice expressing Cre under the control of the rat insulin pro-
moter (RIP Cre). TRAF2 mRNA and protein were expressed 
in TRAF2loxP/loxP islets but depleted in islets from TRAF2 
mice (Fig. 3, A and B). TRAF2 islets showed high cell- 
intrinsic accumulation of NIK with hyper-phosphorylation 
of IKK (Fig. 3 C). TRAF2 islets exhibited increased p100 
processing into p52 and higher levels of RelB. In contrast, 
IB levels were not changed in TRAF2 islets, indicating 
that IKK and canonical NF-B signaling were not activated. 
Thus, loss of TRAF2 results in cell-intrinsic constitutive acti-
vation of NIK in pancreatic  cells.
Chow-fed TRAF2 mice exhibited normal weight gain 
over the experimental period of 8 wk and normal glucose 
tolerance at 8 wk of age (not depicted). They also had mildly 
elevated nonfasted blood glucose levels (Fig. 3 D) compared 
with floxed littermates and RIP Cre/+ controls. By 16 wk of 
age, chow-fed TRAF2 mice showed very mild glucose in-
tolerance (Fig. 3 E) and no significant difference in insulin 
secretion (Fig. 3 F) compared with WT mice. However, in 
a DIO model, TRAF2 mice showed greatly exacerbated 
glucose intolerance compared with WT mice (Fig. 3 G). We 
next examined in vivo insulin secretion (i.v. GTT) to test 
whether this related to a  cell defect. In this experiment, 
DIO TRAF2 mice exhibited a reduction in first-phase in-
sulin secretion (Fig. 3 H). These data demonstrate that  cell–
intrinsic activation of NIK results in impaired glucose tolerance 
due to reduced  cell function.
NIK activation influences  cell mass in a model  
diet-induced obesity
To determine whether the reduction in insulin secretion 
was due to decline in insulin production, we determined 
total pancreatic insulin content and  cell area. On a chow 
diet, pancreata from TRAF2 mice showed similar total 
insulin content as WT mice and normal  cell area (Fig. 3, 
chow-fed mice at 8-wk-old (***, P < 0.001) and in 15 TRAF2loxP/loxP (WT), 5 RI Cre (WT), and 12 TRAF2 chow-fed mice at 16 wk of age (n.s.) and in 15  
TRAF2loxP/loxP (WT), 5 RI Cre (WT), and 12 TRAF2 HFD-fed mice at 16 wk old (n.s.). Data are representative of three independent mouse cohorts tested.  
(E) Blood glucose levels were measured in 15 TRAF2loxP/loxP (WT), 5 RI Cre (WT) and 12 TRAF2 chow-fed mice (16 wk old) after i.p. injection of d-glucose (WT, 
dotted line; TRAF2, solid line). Data are representative of three independent mouse cohorts tested. **, P < 0.01. (F) Insulin levels were measured in six 
TRAF2loxP/loxP (WT) and six TRAF2 chow-fed mice (16 wk old) after i.v. injection of d-glucose (WT, dotted line; TRAF2, solid line). Data are representative of 
three independent mouse cohorts tested (n.s.). (G) Blood glucose levels were measured in 15 TRAF2loxP/loxP (WT), 5 RI Cre (WT), and 12 TRAF2 HFD-fed 
mice (16 wk old) after i.p. injection of d-glucose (WT, dotted line; TRAF2, solid line). Data are representative of three independent mouse cohorts tested. 
(***, P < 0.001) (H) Insulin levels were measured in 10 TRAF2loxP/loxP (WT), 5 RI Cre, and 10 TRAF2 HFD-fed mice (16 wk old) after i.v. injection of  
d-glucose (WT, dotted line; TRAF2, solid line). Data are representative of three independent mouse cohorts tested. *, P < 0.05. (I) Pancreatic insulin con-
tent in chow- and HFD-fed WT and TRAF2 mice was determined. The data are mean and SEM derived from five mice per group (chow, n.s.; DIO, *, P < 0.05).  
(J) Total  cell area was determined for chow- and HFD-fed WT and TRAF2 mice by quantification of insulin-positive area in serial graft sections as a 
percentage of total pancreatic exocrine tissue. The data are mean and SEM derived from three mice per group (chow, n.s.; DIO, *, P < 0.05). (K) Insulin 
immunohistochemistry of histological pancreatic sections of chow- and HFD-fed WT and TRAF2 mice is shown. The data are representative images of 
three mice per group. Bars, 100 µm. (L) Insulin-1 and Insulin-2 mRNA expression in chow- and HFD-fed TRAF2loxP/loxP (WT) and TRAF2 from four (Ins1) 
and five (Ins2) islet isolates was determined by RT-PCR and is presented as a fold change relative to WT (n.s.; data are representative of two independent 
experiments). All data are represented as mean ± SEM; p-values were determined using Student’s t test.
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Destabilizing the TRAF2–TRAF3–BIRC2/3 E3 ligase complex 
results in impaired  cell function
The  cell secretory defect in TRAF2 mice suggests that 
 cell–intrinsic NIK activation results in impaired  cell func-
tion. A potential caveat to this interpretation is that TRAF2 is 
also necessary for molecular control over the canonical NF-B 
and JNK/activator protein 1 (AP-1) signaling pathways (Yeh 
et al., 1997). While TRAF2 and TRAF3 are both required to 
suppress NIK activity, TRAF3 differs from TRAF2 as it is not 
involved in NF-B and JNK/AP-1 signaling downstream of 
TNFR family members (Vallabhapurapu et al., 2008). Therefore, 
we examined NIK activation and  cell function in  cell–
specific TRAF3 knockout (TRAF3) mice. TRAF3 islets 
showed reduced mRNA and protein levels of TRAF3 com-
pared with WT islets (Fig. 5, A and B). TRAF3-deficient islets 
Ex vivo glucose-stimulated insulin secretion  
is diminished in TRAF2 islets
In a second approach to establish the  cell–intrinsic defect, 
we challenged TRAF2 islets in a GSIS assay. TRAF2 islets 
exhibited normal basal insulin output at a glucose concentra-
tion of 2 mM (Fig. 4 E). However, when challenged with 
20 mM glucose, TRAF2 islets exhibited a 50% decrease in 
GSIS compared with WT islets. KCl, which induces mem-
brane depolarization to trigger insulin secretion indepen-
dent of glucose, provoked a normal insulin secretory response 
in TRAF2 islets, indicating that insulin content and se-
cretory machinery were intact in these NIK-activated islets. 
Collectively, the in vivo transplant and GSIS data demon-
strate that the metabolic defect observed for TRAF2 mice is 
 cell intrinsic.
Figure 4. Deletion of TRAF2 causes impaired glucose tolerance independent of Cre expression in the hypothalamus. (A) Non-fasted blood 
glucose levels in STZ-treated C57BL/6 recipients transplanted with 150 IEQs of WT (dotted line) and TRAF2 (solid line) islets were determined. Data are 
representative of three independent mouse cohorts, in which 15 TRAF2loxP/loxP (WT), 10 RI Cre (WT), and 14 TRAF2 islet transplant recipients were tested.  
(B) Blood glucose and AUC were assessed in 8 TRAF2loxP/loxP (WT), 4 RI Cre (WT), and 10 TRAF2 islet transplant recipients after i.p. injection of d-glucose 
at day 11 after transplant. Data are representative of three independent mouse cohorts tested. *, P < 0.05. (C) Insulin levels and AUC were assessed in  
6 TRAF2loxP/loxP (WT), 4 RI Cre (WT), and 10 TRAF2 islet transplant recipients after i.v. injection of d-glucose at day 21 after transplant. Data are represen-
tative of three independent mouse cohorts tested. *, P < 0.05. (D) H&E staining and insulin immunohistochemistry of WT and TRAF2 islet grafts are 
shown. Graft  cell area was determined for three WT and three TRAF2 islet grafts by quantification of insulin-positive area in continuous serial graft 
sections. A representative image for each condition is shown. Boxed insets represent magnified area. Differences in graft area are not significant (P > 
0.05). Bar, 100 µm. (E) In vitro GSIS in 2, 11, and 20 mM d-glucose and in KCl conditions in WT and TRAF2 mouse islets was measured. Data are mean 
and SEM derived from six independent islet isolates for each group, and are representative of two independent experiments. **, P < 0.01. All data are rep-
resented as mean ± SEM; p-values were determined using Student’s t test.
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Figure 5. Destabilization of the TRAF2-TRAF3-BIRC2/3 E3 ligase complex results in impaired  cell function. (A) TRAF3 protein levels in WT 
and TRAF3 islets from one WT and one TRAF3 mouse were assessed by immunoblotting. A representative of three independent islet isolates tested per 
genotype is shown. Histogram data depict mean and SEM cumulative densitometry relative to -actin of the three independent experiments. (B) Relative 
expression of islet TRAF3 mRNA in six WT and three TRAF3 islet isolates was determined by RT-PCR. Data are representative of two independent experi-
ments. ***, P < 0.001. (C) Protein levels of NIK, IKK/ phosphorylation, IB, p100 to p52 processing, and RelB in one nonstimulated WT and one 
TRAF3 islet isolate were assessed by immunoblotting. A representative of three independent experiments is shown. Histogram data depict cumulative 
densitometry relative to -actin of the three independent experiments. (D) Non-fasted blood glucose levels were determined in 20 TRAF3loxP/loxP (WT) and 
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12 TRAF3 chow-fed mice (8 wk old; n.s.); in 20 TRAF3loxP/loxP (WT) and 10 TRAF3 chow-fed mice at 16 wk old (n.s.); and in 15 TRAF3loxP/loxP (WT) and  
12 TRAF3 HFD-fed mice (16 wk old). *, P < 0.05. Data are representative of three independent mouse cohorts tested. (E) Blood glucose levels were measured 
in 20 TRAF3loxP/loxP (WT) and 10 TRAF3 chow-fed mice (16 wk old) after i.p. injection of d-glucose (WT, dotted line; TRAF3, solid line). Data are represen-
tative of three independent mouse cohorts tested. ***, P < 0.001. (F) Insulin levels were measured in six TRAF3loxP/loxP (WT) and six TRAF3 chow-fed mice 
(16 wk old) after i.v. injection of d-glucose (WT: dotted line; TRAF3: solid line). Data are representative of three independent mouse cohorts tested.  
*, P < 0.05 at 20 min after injection. (G) Blood glucose levels were measured in 15 TRAF3loxP/loxP (WT), 5 RI Cre (WT) and 12 TRAF3 chow-fed mice (16 wk old) 
after i.p. injection of d-glucose (WT, dotted line; TRAF3, solid line). Data are representative of three independent mouse cohorts tested. ***, P < 0.001.  
(H) Insulin levels were measured in 10 TRAF3loxP/loxP (WT), 5 RI Cre, and 8 TRAF3 HFD-fed mice (16 wk old) after i.v. injection of d-glucose (WT, dotted line; 
TRAF3, solid line). Data are representative of three independent mouse cohorts tested. *, P < 0.05. (I) Pancreatic insulin content in HFD-fed WT and TRAF3 
mice was determined. The data are mean and SEM derived from five mice per group (n.s.; P = 0.072). (J) Total  cell area was determined for HFD-fed WT 
and TRAF3 mice by quantification of insulin-positive area in serial graft sections as a percentage of total pancreatic exocrine tissue. The data are mean 
and SEM derived from three mice per group. *, P < 0.05. (K) In vitro GSIS in 2, 11, and 20 mM d-glucose. KCl conditions in WT and TRAF3 mouse islets 
were measured. Data are mean and SEM derived from six independent islet isolates for each group and are representative of two independent  
experiments. *, P < 0.05. All data are represented as mean ± SEM; p-values were determined using Student’s t test.
 
secretion. Further, these data demonstrate that NIK activa-
tion precipitates  cell failure in a DIO model.
Expression profiling of TRAF2 and TRAF3 islets  
reveals a diabetes gene signature
To determine the molecular basis for islet dysfunction, we 
determined genes that were differentially expressed in both 
TRAF2 and TRAF3 islets compared with WT islets using 
microarray analysis. We identified 26 differentially expressed 
genes common to the chow-fed TRAF2 and TRAF3 islets 
and 35 differentially expressed genes common to the DIO 
TRAF2 and TRAF3 islets compared with respective WT 
controls (Fig. 7 A). The 15 most differentially expressed genes 
within chow and DIO TRAF2 and TRAF3 islets com-
paring logarithmic fold change (logFC) and their function are 
listed in Table 1 and Table S1. Additionally, nine differen-
tially expressed genes overlapped between the chow and DIO 
TRAF2 and TRAF3 islets (Table 1, top six most differen-
tially expressed genes highlighted in bold). The majority of the 
differentially expressed genes were up-regulated in TRAF2 
and TRAF3 islets. This indicates that NIK and the nonca-
nonical NF-B pathway activate rather than repress a select 
transcriptional program in pancreatic  cells. The up-regulation 
of Tph1, Lrrc55, Hcn1, Tnfrsf11b, Rasgrp1, Grem2, and Pde7b 
in TRAF2 and TRAF3 islets was validated by RT-PCR 
in a series of independent experiments (Fig. 7 B). Gene on-
tology analysis highlighted regulators of growth and prolifer-
ation, metabolic genes, potassium channel components, and 
vesicle-associated genes, many of which are associated with 
diabetes in animal models (Table 2). Significantly, many of 
the differentially expressed genes have been identified in human 
studies such as GWAS, linking genes such as Bcat1 (Grimm 
et al., 2003; Rampersaud et al., 2007; Keller et al., 2008; Chen 
et al., 2013), Gbp4 (Westra et al., 2013), Igfbp5 (Jehle et al., 
1998; Ambra et al., 2014), Kcnj5 (Li et al., 2012; Cnop et al., 
2014; Dayeh et al., 2014), Matn2 (Ambra et al., 2014; Cnop 
et al., 2014), Rerg, Rph3a, Slca13, and Pde7b (Dayeh et al., 
2014), Sftpd (Ortega et al., 2013), Rasgrp1 (Qu et al., 2009; 
Taneera et al., 2012; Li et al., 2013), or Tnfrsf11b (Olesen 
et al., 2005; Bradfield et al., 2011; Cnop et al., 2014) to type 1 
showed constitutive, cell-intrinsic hyperaccumulation of NIK, 
higher levels of phospho-IKK, an increased p52 to p100 ratio 
and increased RelB levels (Fig. 5 C). Canonical NF-B and 
JNK signaling in response to TNF, however, was normal in pan-
creatic islets lacking TRAF3 (unpublished data), as has been 
described in other cell types (Gardam et al., 2011).
Chow-fed TRAF3 mice exhibited normal weight in-
crease, normal glucose tolerance at 8 wk of age (not depicted), 
and normal nonfasted blood glucose levels (Fig. 5 D), but they 
displayed mildly decreased glucose tolerance and insulin secre-
tion at 16 wk of age compared with WT mice (Fig. 5, E and F). 
In a DIO model, TRAF3 mice presented with abnormally 
high nonfasted blood glucose levels (Fig. 5 D), impaired glu-
cose tolerance (Fig. 5 G), and a reduction in GSIS in vivo 
compared with WT mice (Fig. 5 H). Analysis of total pan-
creatic insulin content and  cell mass revealed that DIO 
TRAF3 mice exhibited increased pancreatic insulin content 
compared with WT mice due to an increase in their  cell 
area (Fig. 5, I and J). Further to this, TRAF3 islets showed 
reduced GSIS ex vivo but a normal insulin secretory response 
to KCl (Fig. 5 K). Thus, TRAF3 mice phenocopy TRAF2 
mice with  cell–intrinsic NIK hyperactivation and impaired 
 cell function.
Loss of BIRC proteins results in impaired  cell function
The key role of TRAF2 and TRAF3 in regulation of NIK is 
the recruitment and directed control of the E3 ligase activity 
of BIRC proteins toward NIK. As MV1-induced NIK acti-
vation occurs through BIRC2 and BIRC3 degradation, we 
hypothesized genetic ablation of BIRC2 and BIRC3 in  cells 
would trigger a  cell defect. Mice that lack both BIRC2 and 
BIRC3 in their  cells (BIRC2/3) exhibit islet-intrinsic NIK 
hyperactivation, as indicated by increased p100 processing 
(Fig. 6 A) with impaired glucose tolerance and reduced insu-
lin secretion in a DIO model (Fig. 6, B and C). These data 
demonstrate that all components of the TRAF2–TRAF3–
BIRC2–BIRC3 E3 ligase complex are required to provide 
the  cell protective circuit that reigns in the deleterious acti-
vation of NIK, which suggests that firm regulation of NIK 
in  cells is essential to control glucose sensing and insulin 
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as NIK activators in a DIO mouse model and in human obe-
sity. Both RANKL and TNF levels are elevated in mouse 
models of obesity and in T2D subjects (Hotamisligil et al., 
1995; Kiechl et al., 2013). Blockade of TNF or RANKL im-
proved glucose tolerance in mouse models of obesity (Uysal 
et al., 1997; Kiechl et al., 2013). Further, TNF inhibition has 
been shown to alleviate the metabolic syndrome in several 
human studies (Bernstein et al., 2006; Marra et al., 2007; 
Campanati et al., 2013).
Our data furthers studies showing that diet-induced obe-
sity induces NIK in peripheral insulin-dependent tissues such 
as liver (Sheng et al., 2012) and muscle (Choudhary et al., 
2011). Further evidence for a crucial involvement of NIK in 
whole body glucose homeostasis comes from studies of NIK 
knockout mice, which are hypoglycemic and exhibit improved 
glucose tolerance on a chow diet (Sheng et al., 2012). Accu-
mulation of NIK is associated with decreased glucose uptake 
and type 2 diabetes. These data identify NIK as a critical new 
 cell–intrinsic signaling node in diabetes integrating a tran-
scriptional network that controls glucose homeostasis.
DISCUSSION
We have identified NIK as a novel mechanism of  cell dys-
function in obesity. Acute NIK activation using a pharmaco-
logical approach disrupts glucose homeostasis in a zebrafish 
model, and induces  cell dysfunction in mouse islets, but 
also in human islets, highlighting the importance of the NIK 
pathway in human islet physiology as a negative regulator of 
 cell function. As we have demonstrated, pancreatic  cells 
in a model of obesity and glucose intolerance present with 
 cell–intrinsic NIK activation and a decrease in  cell insulin 
secretory capacity. We could demonstrate that NIK was in-
duced by inflammatory cytokines TNF and RANKL in pan-
creatic mouse islets. Both cytokines constitute good candidates 
Figure 6. Genetic ablation of BIRC2 and 3 phenocopies TRAF2 and TRAF3 mice. (A) Protein levels of p100 to p52 processing in one WT and 
one BIRC2/3 islet isolate were assessed by immunoblotting. A representative of three independent experiments is shown. Histogram data depicts cumu-
lative densitometry relative to -actin of the three independent experiments. (B) Blood glucose and AUC were measured in 20 WT and 6 BIRC2/3 HFD-
fed mice (16 wk old) after i.p. injection of d-glucose. Data are representative of three independent mouse cohorts tested. **, P < 0.01. (C) Insulin levels and 
AUC were measured in six WT and six BIRC2/3 HFD-fed mice (16 wk old) after i.v. injection of d-glucose. Data are representative of three independent 
mouse cohorts tested. *, P < 0.05. All data are represented as mean ± SEM; p-values were determined using Student’s t test.
Figure 7. Differentially regulated genes and expression validation by RT-PCR in TRAF2 and TRAF3 islets. (A) Venn diagram of the number 
of differentially regulated genes in TRAF2 chow, TRAF3 chow, TRAF2 DIO, and TRAF3 DIO mice compared with respective WT controls is shown.  
(B) A validation of gene microarray results was assessed by RT-PCR in TRAF2 and TRAF3 islets. The expression levels of Tph1, Lrrc55, Hcn1, Tnfrsf11b 
(OPG), Rasgrp1, Grem2, and Pde7b were examined in five TRAF2 and five TRAF3 islet isolates and are presented as a fold change relative to three TRAF2loxP/loxP 
and three TRAF3loxP/loxP (WT) islet isolates. Data are representative of two independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are 
represented as mean ± SEM; p-values were determined using Student’s t test.
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activation of the transcription factor cAMP response element-
binding (CREB) levels, which stimulates gluconeogenesis. 
This process is controlled by cAMP-dependent PKA phos-
phorylating and activating CREB. We identified Pde7b as a 
highly expressed gene in islets with constitutively activated 
NIK (TRAF2 and TRAF3 islets). Pde7b, which encodes 
for phosphodiesterase 7b (PDE7B), is involved in the con-
version of cAMP to AMP, thereby decreasing cAMP second-
ary messenger activity (Hetman et al., 2000). cAMP regulates 
glucose sensing and insulin secretion in pancreatic  cells, 
through both PKA-dependent and-independent mechanisms 
(Ämmalä et al., 1994; Leclerc and Rutter, 2004). Significantly, 
in muscle (Choudhary et al., 2011) and increased hepatic glu-
cose output by the liver (Sheng et al., 2012). Thus, NIK is 
emerging as a global molecular factor in obesity, therefore, 
these data highlight the possibility of systemic NIK inhibition 
as a potential therapeutic target to reduce hepatic glucose pro-
duction and improve muscle uptake of glucose, while simul-
taneously preserving  cell function.
As we showed for pancreatic islets in diet-induced obesity, 
NIK levels are increased in the livers of genetically (db/db) and 
diet-induced obese mice (Sheng et al., 2012). Hepatocyte-specific 
NIK overexpression increased hepatic glucose output, pre-
sumably by phosphorylation and concomitant elevation and 
Table 1. Top 15 most highly differentially expressed genes in TRAF2 and TRAF3 islets (chow and DIO)
Genea Log FCb Associated functionc
TRAF2  
chow
TRAF3  
chow
TRAF2  
DIO
TRAF3  
DIO
Tph1 (tryptophan hydroxylase 1) - - 6.88 6.33 aromatic amino acid family metabolic process, bone 
remodeling, neuron projection, serotonin synthesis
Lrrc55 (leucine rich repeat 
containing 55)
3.78 2.90 5.00 5.04 potassium ion transport, BK channel auxiliary subunit
Sftpd (surfactant associated 
protein D)
3.12 2.28 4.07 3.15 phospholipid homeostasis, regulation of phagocytosis, 
LPS binding
Gbp8 (guanylate-binding 
protein 8)
3.16 - 3.59 3.36 large IFN-–induced GTPase
Syt10 (synaptotagmin X) 3.20 - 3.53 3.24 regulation of Ca2+-dependent exocytosis, cytoplasmic 
vesicle
Crispld2 (cysteine-rich secretory 
protein LCCL domain 
containing 2)
3.36 3.33 - 2.68 extracellular matrix (ECM) component, heparin binding, 
LPS binding, vesicle transport
Hcn1 (hyper-polarization-
activated, cyclic nucleotide-
gated K+ 1)
2.75 2.40 3.36 3.24 potassium ion transport; voltage-gated potassium 
channel, sensitivity to cAMP
Fbxw24 (F-box and WD-40 
domain protein 24)
2.91 1.82 3.48 2.99 protein coding gene, unknown function
Tnfrsf11b (tumor necrosis factor 
receptor superfamily, member 
11b)
- - 3.20 3.19 osteoprotegerin (OPG), ECM organisation, regulation of 
differentiation, negative regulation of bone resorption, 
decoy receptor for RANKL
Matn2 (matrilin 2) - - 3.42 2.92 ECM, formation of filamentous networks, neuron cell 
migration,Ca2+-binding,
Rerg (RAS-like, estrogen-
regulated, growth-inhibitor)
2.13 1.56 3.30 3.04 RAS superfamily of GTPases, negative regulator of cell 
growth/proliferation
Rasgrp1 
(RAS guanyl releasing protein 
1)
3.16 3.07 - 2.93 GEF activity: activation of Ras and Rho GTPases, Ca2+ 
binding
Fmo1 
(flavin containing 
monooxygenase 1)
- - 3.16 2.55 drug metabolic process; oxidation-reduction process; 
NADPH oxidation; organic acid metabolic process
Grem2 (gremlin 2 homolog, 
cysteine knot superfamily 
(Xenopus laevis))
2.19 1.49 2.54 2.28 regulator of osteoblast differentiation and 
osteogenesis; cytokine, heparin binding, negative 
regulation of BMP signaling pathway
Gbp4 (guanylate binding 
protein 4)
2.29 2.44 large IFN-–induced GTPase negative regulation of 
protein ubiquitination
aGene symbol and gene name.
bLog fold change of differential gene expression in chow and DIO TRAF2 and TRAF3 islets.
cAssociated gene function according to DAVID Bioinformatics Database and Mouse Genome Database (MGD) at http://www.informatics.jax.org (September 2014).
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C57BL/6 background; The Jackson Laboratory) to generate  cell–specific 
knockout mice (TRAF2, TRAF3, and BIRC2/3).
Zebrafish studies. WT zebrafish larvae were injected pericardially at 6 d 
after fertilization with 2 nl of 10 mM MV1 in 10% DMSO or 10% DMSO 
as described (Hesselson et al., 2009). Free glucose levels were analyzed 
6 h after injection using a fluorescent glucose assay kit (Biovision; Jurczyk 
et al., 2011).
In vivo studies. For islet transplantation, 150 hand-counted primary islet 
equivalents isolated from male and female donor mice were transplanted into 
syngeneic diabetic male C57BL/6 recipients as previously described (Grey 
et al., 2003). Mice in the DIO model were fed a diet providing 45% calories 
from fat (lard/safflower oil) ad libitum. Glucose tolerance tests (i.p. 2 g/kg 
and i.v. 1 g/kg body weight) after a 16-h fast were performed on female 
TRAF2, TRAF3, and BIRC2/3 mice and respective floxed and RIP 
Cre controls mice as previously described (Cantley et al., 2013). Blood samples 
for insulin ELISA (mouse ultra-sensitive kit; Crystal Chem) were collected 
using 5-µl micro-capillary tubes (Drummond microcaps; Sigma-Aldrich). 
Insulin secretory capacity was determined by normalizing insulin levels or 
insulin secretion measured by AUC to total  cell area. Islets were isolated 
as previously described (Zammit et al., 2013), from male and female donors 
for GSIS, RNA extraction, and Western blot protein extraction. In vivo 
mouse physiology experiments comprise data from at least three indepen-
dent cohorts.
Analysis of TRAF2 and TRAF3 mRNA expression in isolated islets. 
Isolated mRNA (QIAschredder, RNEasy Plus Mini kit; QIAGEN) was 
reverse transcribed (Quantitect Reverse Transcription kit; QIAGEN). mRNA 
expression was determined by Real Time-PCRs using FastStart SYBR Green 
Master Mix (Roche). PCR reactions were performed with the following 
primers and normalized to the house-keeping gene Cyclophillin A (CpH, 
sense 5-TGGACCAAACACAAACGGTTCC-3 and antisense 5-ACA-
TTGCGAGCAGATGGGGTAG-3; TRAF2, sense 5-TCTGCCTGACC-
AGCATCCTC-3 and antisense 5-AATGCCTTCTTCATACAGGCC-
TTC-3; TRAF3, sense 5-CAGCGTGCCAAGAAAGCATC-3 and antisense 
5-CGCACAACCTCTGCCTTCAT-3). Initial denaturation was performed 
Pde7b and Traf2 were both recently shown to be differen-
tially methylated in a genome-wide analysis of human T2D 
pancreatic islets (Dayeh et al., 2014). Pde7b was found to be 
differentially expressed in human T2D pancreatic islets as as-
sessed by RT-PCR, and its overexpression caused a reduc-
tion in glucose-stimulated insulin secretion in vitro (Dayeh 
et al., 2014). This suggests that overactivation of NIK may 
provide a direct link between regulation of cAMP levels and 
CREB activity, both in liver and in islets.
Inflammation has emerged as a key factor in the patho-
genesis of the metabolic syndrome acting at the level of mus-
cle and liver to induce insulin resistance, at adipocytes to 
drive elaboration of cytokines, and at the level of the  cell. 
Key signaling pathways include the JNK and canonical 
NF-B pathways. Here, we demonstrate NIK levels are ele-
vated in pancreatic islets isolated from diet-induced obese 
mice, which exhibited decreased insulin secretory capacity. 
Further, several genetic mouse models of constitutive  cell–
intrinsic NIK activation present impaired glucose-stimulated 
insulin secretion in diet-induced obesity. Thus, NIK acts as a 
critical signaling node that regulates a transcriptional network 
to control glucose homeostasis. NIK activation in obesity is a 
feature of pancreatic  cells, liver and muscle providing a tissue-
spanning mechanistic understanding of the global effects of 
obesity in the metabolic syndrome.
MATERIALS AND METHODS
Mouse strains. C57BL/6 mice were sourced from Australian BioResource 
(Mossvale, NSW, Australia). TRAF2loxP/loxP, TRAF3loxP/loxP (C57BL/6 back-
ground; gift from R. Brink, Garvan Institute, NSW, Australia) and Birc3/ 
mice containing Birc2loxP/loxP (C57BL/6 background; gift from D. Vaux, 
Walter and Eliza Hall Institute, VIC, Australia) were crossed with RIP-Cre 
mice (Cre driven by the rat insulin 2 promoter; Tg[Ins2-cre]25Mgn/J, 
Table 2. Gene ontology and diabetes association of differentially expressed genes in TRAF2 and TRAF3 islets (chow and DIO)
chow DIO
Gene ontologya
Regulation of cell growth, proliferation, apoptosis Adora1, Bcat1, Gfra3, Grem2, Rasgrp1, Rerg, 
Sftpd, Socs2
Cish, Fmo1, Igfbp5, Ngfr, Prok1, Tph1, Tnfrsf11b
Metabolic processes Adora1, Bcat1, Grem2, Ogdhl, Slca13, Wipi1 Fmo1, Ivd, Pde7b, Tph1, Srbd1
Potassium channel component Hcn1, Kcnk10, Lrrcc55 Hcn1, Kcnj5
GPCR or GTPase related Adora1, Gbp4, Gbp10, Gpr126, Gpr182, Penk, 
Rasgrp1
Cish, Gbp8, Gpr110, Kcnj5, Rph3a
Vesicle-associated Crispld2, Krtap13-1, Rasgrp1, Wipi1 Rph3a, Syt10, Tmem2
Diabetes associationb
associated with type 1 diabetic phenotype in 
mouse models
Adora1, Bcat1, Gbp4, Gbp10, Hcn1, Rasgrp1 Fmo1, Ngfr, Tnfrsf11b
associated with type 2 diabetic phenotype in 
mouse models
Adora1, Bcat1, Gfra3, Gpr126, Hcn1, Kcnk10, 
Penk, Rasgrp1, Rerg, Sftpd, Socs2, Tnfrsf9, Wipi1
B3galnt1, B3galt1, Cish, Cym, Fmo1, Igfbp5, 
Kcnj5, Ngfr, Tnfrsf11b
associated with T1D in humans Gbp4, Rasgrp1 Igfbp5, Tnfrsf11b
associated with T2D in humans Bcat1, Rasgrp1, Sftpd Adarb2, Igfbp5, Ivd, Kcnj5, Pde7b, Rerg, Rph3a, 
Slca13, Tnfrsf11b
aGenes grouped by associated biological function according to DAVID Bioinformatics Database.
bGenes associated with T1D and/or T2D in humans; genes associated with a diabetic phenotype in mouse models.
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